RxDoctor Payments Data

Anil Parikh, MD

Psychiatry · Fairlawn, OHNPI 1437218922

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $249,150 of the $293,230 with a category attached, or 85.0%. AbbVie accounts for 99.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $91,068 and has fallen 89.2% since, to $9,866 in 2025. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$293,230in general payments, 2019–2025

Across 516 payments — averaging $568.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • E.r. Squibb & Sons, L.L.C.$27
  • Takeda Pharmaceuticals U.S.A., Inc.$19
  • Banner Life Sciences, LLC$19
  • Lundbeck LLC$18
  • plus $27 from 2 others

What the payments were for

  • Consulting fees$1,9801%
  • Speaking & faculty fees$249,15085%
  • Travel & lodging$36,88413%
  • Food & beverage$5,1882%
  • Education$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293,230 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$91,087
Medicare patients
64
Services billed
1,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$67,397
TrintellixVortioxetine Hydrobromide24$13,558
Lurasidone Hcl44$13,201
Atomoxetine Hcl54$5,307
Duloxetine Hcl230$4,426
Clozapine26$3,748
Buspirone Hcl353$3,513
Vilazodone Hcl25$3,249
Bupropion XlBupropion Hcl110$2,606
Mirtazapine208$2,479
Olanzapine99$2,387
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$2,033
Hydroxyzine Hcl98$1,987
Ziprasidone Hcl68$1,970
Fluoxetine Hcl36$1,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$291,125$67,39748 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$13,55824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Fairlawn

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →